A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

This is a 2-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients.

Completed

Looking for future studies?

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Obese men and nonpregnant women at least 18 years of age with a specific body mass index (height and weight ratio) required by the study

Exclusion criteria

Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood sugar)

Treatment and study plan

MK0557

Drug

Primary outcomes

Body weight after 1 year of treatment. Safety and tolerability for 2 years.

Time frame: After 1 & 2 years of treatment

Secondary outcomes

Durability of weight loss over two years.

Time frame: Over two years.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients

Important dates

Study start: 2003
Primary completion: 2005
Study completion: 2005
First posted: Sep 28, 2004
Registry last updated: Jan 2, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed